Fjarde AP Fonden Fourth Swedish National Pension Fund Cuts Position in IQVIA Holdings Inc. (NYSE:IQV)

Fjarde AP Fonden Fourth Swedish National Pension Fund trimmed its position in IQVIA Holdings Inc. (NYSE:IQV) by 15.2% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 30,056 shares of the medical research company’s stock after selling 5,400 shares during the quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund’s holdings in IQVIA were worth $5,299,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the company. Caitong International Asset Management Co. Ltd raised its holdings in shares of IQVIA by 99.3% in the 1st quarter. Caitong International Asset Management Co. Ltd now owns 558 shares of the medical research company’s stock worth $98,000 after purchasing an additional 278 shares during the period. S Bank Fund Management Ltd acquired a new stake in IQVIA during the 1st quarter valued at approximately $303,000. National Pension Service grew its stake in IQVIA by 10.6% during the 1st quarter. National Pension Service now owns 317,938 shares of the medical research company’s stock valued at $56,052,000 after purchasing an additional 30,597 shares in the last quarter. MSH Capital Advisors LLC grew its stake in IQVIA by 11.6% during the 1st quarter. MSH Capital Advisors LLC now owns 2,371 shares of the medical research company’s stock valued at $418,000 after purchasing an additional 246 shares in the last quarter. Finally, Clal Insurance Enterprises Holdings Ltd grew its position in shares of IQVIA by 436.7% in the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 161 shares of the medical research company’s stock worth $28,000 after acquiring an additional 131 shares in the last quarter. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

IQVIA Stock Up 0.9%

Shares of IQVIA stock opened at $191.18 on Friday. The business’s fifty day moving average price is $170.40 and its two-hundred day moving average price is $168.83. The company has a debt-to-equity ratio of 2.45, a current ratio of 0.84 and a quick ratio of 0.84. The company has a market capitalization of $32.50 billion, a P/E ratio of 27.67, a PEG ratio of 2.08 and a beta of 1.30. IQVIA Holdings Inc. has a 1-year low of $134.65 and a 1-year high of $252.88.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share for the quarter, beating the consensus estimate of $2.77 by $0.04. The business had revenue of $4.02 billion during the quarter, compared to analyst estimates of $3.96 billion. IQVIA had a return on equity of 30.05% and a net margin of 7.88%. The company’s revenue was up 5.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.64 earnings per share. As a group, research analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on IQV shares. Redburn Partners set a $188.00 target price on IQVIA in a research report on Friday, May 23rd. Robert W. Baird lifted their target price on IQVIA from $159.00 to $196.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 23rd. UBS Group lifted their target price on IQVIA from $185.00 to $225.00 and gave the stock a “buy” rating in a research report on Wednesday, July 23rd. Hsbc Global Res lowered IQVIA from a “strong-buy” rating to a “hold” rating in a research report on Friday, April 25th. Finally, JPMorgan Chase & Co. decreased their target price on IQVIA from $232.00 to $177.00 and set an “overweight” rating for the company in a research report on Monday, May 19th. Seven investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $228.62.

Insider Buying and Selling at IQVIA

In other IQVIA news, insider Eric Sherbet sold 5,800 shares of IQVIA stock in a transaction that occurred on Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total value of $1,102,290.00. Following the transaction, the insider owned 27,178 shares in the company, valued at approximately $5,165,178.90. The trade was a 17.59% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Keriann Cherofsky sold 549 shares of IQVIA stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total value of $105,149.97. Following the completion of the transaction, the insider owned 2,910 shares in the company, valued at $557,352.30. The trade was a 15.87% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 1.60% of the company’s stock.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.